Phoenix Life Sciences International Limited.
Phoenix Life Sciences International Limited. (PLSI): 15 pipeline candidates · 4 clinical trials. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
N/A
D/E 0.13 · 0% dilution
Lead: Phase 2
15 candidates
N/A
N/A
A transparent, data-derived signal for Phoenix Life Sciences International Limited.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$202K
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (15 candidates)
| Drug | Phase |
|---|---|
| activated cannabinoid | Preclinical |
| magrolimab | Phase 2 |
| medi-mist oral spray | Preclinical |
| medi-strip relaxation | Preclinical |
| medijane transdermal patches | Preclinical |
| obeldesivir | Phase 2 |
| phoenix auto | Preclinical |
| phoenix metabolic | Preclinical |
| phoenix mood | Preclinical |
| phoenix neuro | Preclinical |
Showing 10 of 15 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in Phoenix Life Sciences International Limited.'s pipeline?
Phoenix Life Sciences International Limited. (PLSI) has 15 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Phoenix Life Sciences International Limited.'s lead drug candidate?
Phoenix Life Sciences International Limited.'s most advanced tracked candidate is activated cannabinoid (Preclinical) for inflammation, muscle spasms, neuropathic pain.
Get the full picture on Phoenix Life Sciences International Limited.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.